(Q37096055)

18 August 2017

1 reference

title

Pharmacogenomics of anti-TB drugs-related hepatotoxicity (English)

1 reference

18 August 2017

1 reference

1 reference

Puspita Das Roy

1

1 reference

PubMed ID

18303967

18 August 2017

Mousumi Majumder

series ordinal

2

1 reference

PubMed ID

18303967

18 August 2017

Bidyut Roy

series ordinal

3

1 reference

18 August 2017

1 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

3

1 reference

18 August 2017

311-321

1 reference

An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes

18 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Criteria of drug-induced liver disorders. Report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Isoniazid Hepatotoxicity in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Effects of long-term rifampicin administration in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

An official ATS statement: hepatotoxicity of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Anti-tuberculosis medication and the liver: dangers and recommendations in management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Oxidation of hydrazine metabolites formed from isoniazid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5'-flanking region.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.3.311

21 January 2018

Identifiers

DOI

10.2217/14622416.9.3.311

1 reference

18 August 2017

1 reference

PubMed ID

18303967